In craniopharyngiomas, the MAPK/ERK pathway can be activated via mutations in the BRAF gene (as in the PCPs subtype), or by paracrine stimulation by secondary mediators such as interleukins and growth factors (as in the ACPs variant). The gene discussed is BRAF; the disease is craniopharyngioma.